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Background: Hereditary angioedema (HAE) is a rare, debilitating, and potentially life-threatening disease
characterized by recurrent edema attacks. Important advances in HAE treatment have been made, including
the development of new therapies for treating or preventing attacks. Nevertheless, the disease is still
frequently misdiagnosed and inappropriately treated, potentially exposing patients with laryngeal attacks to
the risk of asphyxiation.
Methods: The Icatibant Outcome Survey (IOS) is an international, observational study that documents the
clinical outcome of HAE patients eligible for treatment with icatibant. Patient ages at first symptoms and at
diagnosis were recorded at enrolment, and the delay between first symptoms and diagnosis was calculated.
Results: The median [range] diagnostic delay in HAE type I and II patients across eight countries was 8.5 years
[0–62.0]. The median delay in diagnosis was longer for HAE type II versus type I (21 versus 8 years,
respectively), although this did not quite reach statistical significance.
Conclusions: Although it can be difficult to differentiate HAE symptoms from those of more common
angioedema sub-types (e.g. idiopathic or acquired angioedema), our results show that HAE type I and II
patients have an unacceptable delay in diagnosis, even those with a family history of the disease. Raising
physician awareness of this disabling and potentially fatal disease may lead to a more accurate diagnosis and
timely treatment.
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Hereditary angioedema (HAE), due to C1-inhibitor
(C1-INH) deficiency, is a rare disease with an estimated
frequency of 1:50 000 [1]. HAE is caused by mutations in
the C1-INH gene that results in reduced levels (type I) or
function (type II) of C1-INH protein [2]. The deficiency of
C1-INH leads to increased activation of the contact system,
which generates elevated levels of bradykinin (the mediator
of the increased vascular permeability) and the resulting
edema observed in HAE patients [3]. The clinical features
of HAE include recurrent episodes of edema, which usually
last for 2–5 days. The skin, gastrointestinal tract, and upper
airway are most commonly affected. Delayed treatment of
laryngeal swelling can result in death [1,4].* Correspondence: andrea.zanichelli@unimi.it
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reproduction in any medium, provided the orThe rarity of HAE, the fact that its symptoms overlap
with those of other forms of angioedema and, in cases of
abdominal attack, can appear to be a surgical emergency,
mean that it is frequently misdiagnosed. Consequently,
HAE patients may experience considerable delays in
diagnosis [5,6]. Previous nationwide surveys in Spain and
Denmark have reported mean delays in diagnosis of 13.1
and 16.3 years, respectively [5,6]. In an international
web-based survey, 313 patients with HAE reported visit-
ing an average of 4.4 physicians over an average of 8.3
years before receiving an accurate HAE diagnosis [7].
Without an accurate diagnosis, HAE patients may not re-
ceive treatment that can effectively treat their attacks. In-
appropriate treatment could result in higher morbidity
and mortality, adverse events, and unnecessary surgical
interventions [8,9].
Recently published studies and guidelines [10-18] have
resulted in an increased awareness of HAE in the scientificral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Age at first symptoms and diagnosis, and delay in diagnosis by patient type
N Median Q1 Q3 Min Max Mean Standard deviation p-value
Age at first symptoms (years) Male 61 13.0 6.0 20.0 1.3 60.0 15.9 12.53 0.199
Female 92 11.5 5.0 18.0 0.2 77.0 13.6 12.15
HAE type I 140 12.0 6.0 19.0 0.2 77.0 14.4 12.29 0.870
HAE type II 13 13.0 6.0 18.0 2.0 50.0 15.3 13.12
FH+ 106 13.0 6.0 19.0 0.2 50.0 13.7 9.42 0.513
FH- 32 14.0 5.0 26.5 0.8 77.0 19.6 19.60
Total 153 12.0 6.0 19.0 0.2 77.0 14.5 12.32
Age at diagnosis (years) Male 66 25.1 17.9 33.0 9.1 68.3 27.6 14.06 0.844
Female 104 23.3 15.8 38.3 0.0 77.3 28.1 17.37
HAE type I 157 22.1 16.1 36.0 0.0 77.3 27.3 15.87 0.080
HAE type II 13 31.8 24.2 43.5 3.3 74.2 34.9 18.18
FH+ 121 24.4 16.2 35.2 0.0 74.2 26.9 14.96 0.509
FH- 33 22.3 17.1 45.0 3.8 77.3 30.5 19.10
Total 170 24.3 16.9 36.2 0.0 77.3 27.9 16.13
Delay between first symptoms and diagnosis (years) Male 60 8.5 3.0 17.0 0.0 60.0 11.2 10.97 0.771
Female 92 8.5 1.0 24.0 0.0 62.0 13.9 14.88
HAE type I 139 8.0 2.0 20.0 0.0 62.0 12.2 13.35 0.051
HAE type II 13 21.0 7.0 30.0 0.0 42.0 19.6 13.80
FH+ 106 8.5 2.0 21.0 0.0 57.0 12.5 12.94 0.476
FH- 31 6.0 1.0 20.0 0.0 62.0 10.8 13.38
Total 152 8.5 2.0 21.0 0.0 62.0 12.9 13.5
FH+, positive family history; FH-, negative family history; Q1, lower quartile; Q3, upper quartile.
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Icatibant Outcome Survey (IOS) is an international, obser-
vational study that documents the clinical outcome of
HAE patients eligible for treatment with icatibant. Here,
we report the delay in diagnosis in adult patients with type
I or II HAE.
Material and methods
Participants
IOS registry data from 171 HAE type I and II patients
(female/male: 105/66; HAE type I/II: 158/13) from cen-
ters in Germany (N = 46), Spain (N = 45), Italy (N = 30),Table 2 Delay in diagnosis by country
N Median (years) Q1 Q3
Germany 41 2.0 0.0 9.0
Spain 40 13.0 3.5 21.5
Italy 30 15.0 4.0 21.0
France 15 7.0 4.0 24.0
Denmark 12 11.5 3.0 22.5
UK 12 5.5 1.0 16.5
All 150 8.5 2.0 21.0
Due to the low number of patients in Sweden (N = 1) and Israel (N = 1), these patieFrance (N = 18), the UK (N = 17), Denmark (N = 13),
Israel (N = 1) and Sweden (N = 1) were analyzed.
HAE type I was diagnosed in symptomatic patients
when both C1-INH concentration and function were
below normal; HAE type II was diagnosed in symptom-
atic patients when C1-INH concentration was normal or
above normal, and function was below normal. The nor-
mal ranges (according to local reference values) for C1-
INH concentration and function were 15–50 mg/dL and
70–130%, respectively. Patients diagnosed prior to the
onset of symptoms, i.e. on the basis of family history,
were excluded from this analysis.Min Max Mean Standard deviation
0.0 62.0 9.0 13.91
0.0 60.0 15.4 13.74
0.0 57.0 15.7 14.14
2.0 38.0 14.3 13.47
0.0 34.0 13.6 11.68
0.0 20.0 8.0 7.79
0.0 62.0 12.8 13.47
nts have been excluded from the analysis.
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IOS is an international, multicenter, observational pa-
tient registry for patients treated with icatibant (Firazyr®).
This analysis is based on data collected between July
2009 and June 2012. IOS is conducted in accordance
with the Declaration of Helsinki, and the International
Conference on Harmonization Good Clinical Practice
Guidelines. After approval from local Ethics Committees
and/or Health Authorities (where applicable) had been
obtained by the center, all patients provided written in-
formed consent.
Demographic and diagnostic information were collected
from the patient at enrollment. Patient ages at first symp-
toms and at diagnosis were recorded, and the delay be-
tween first symptoms and diagnosis was calculated.
Statistical analyses
In order to compare the age at diagnosis, the age at first
symptoms, and the delay between first symptoms and diag-
nosis, the Wilcoxon–Mann–Whitney test was used. The
one-way analysis of variance with multiple comparisons
(‘least significant difference method’ from Fisher) was
used for the comparison between countries (Sweden and
Israel were excluded from this analysis due to low patient
numbers). The level of statistical significance chosen was
alpha = 0.05.
Results
The median [range] delay in diagnosis in HAE type I and
II patients (N = 152) was 8.5 years [0.0–62.0]. The median
age at first symptoms (N = 153) was 12.0 years [0.2–77.0]
and the corresponding median age at diagnosis (N = 170)
was 24.3 years [0.0–77.3]. The difference observed in the
delay in diagnosis between patients with HAE type I and
patients with HAE type II was almost significant (8.0 [0.0–
62.0] versus 21.0 years [0.0–42.0]; p = 0.051). However, no
difference in delay in diagnosis was found between female
and male patients, or between symptomatic patients with a
positive and a negative family history (Table 1).
The diagnostic delay was markedly different between
countries; ranging from 2.0 years [0.0–62.0] (Germany) to
15.0 years [0.0–57.0] (Italy) (Table 2). However, there were
no trends or statistical significant differences in diagnostic
delay between countries (p = 0.1583), even when analyzed
by year of diagnosis (before 1990, 1990–2000, after 2000).
Nine (5.3%) of the 171 patients included in the IOS
database were diagnosed with HAE type I or II based on
their family history and prior to the onset of symptoms.
These patients therefore have negative delay in diagnosis
values and were excluded from the analyses above.
Discussion
Our study demonstrates that, in a sizable population of
HAE patients from eight countries, the median delay indiagnosis is 8.5 years [range 0.0–62.0]. Possible explana-
tions for the difference in delay in diagnosis between coun-
tries (although not statistically significant; p = 0.1583)
include awareness of HAE among physicians, patient selec-
tion bias during IOS enrolment, or demographic differ-
ences between national patient populations.
We found a considerable difference in delay in diagno-
sis between patients with HAE type I and II, although
not significant (8.0 [0.0–62.0] versus 21.0 years [0.0–
42.0]; p = 0.051). This difference might be due to the fact
that patients are only tested for C1-INH levels, which are
normal or elevated in HAE type II patients. To avoid fur-
ther delay in diagnosis of type II patients, functional C1-
INH analysis also needs to be performed.
Interestingly, patients with a positive HAE family his-
tory were not diagnosed earlier than those with a nega-
tive family history and, currently, only nine (5.3%) of the
171 patients enrolled in IOS were diagnosed prior to the
onset of symptoms, i.e. on the basis of family history.
This indicates that patients may not be adequately in-
formed about the hereditary nature of their disease or,
alternatively, may choose not to seek diagnosis. Undiag-
nosed patients are at a greatly increased risk of prema-
ture death from asphyxiation and of the social and
economic consequences of untreated HAE [9,18]. Active
screening of family members for C1-INH deficiency, ac-
cess to effective, well-tolerated treatment options, and
education of patients and their families with regards to
the benefit of diagnosis and treatment are necessary to
improve this unsatisfactory situation.
Conclusion
Patients with HAE continue to have an unacceptable
delay (median 8.5 years [0.0–62.0]) between the time they
experience their first attack and are adequately diag-
nosed. This delay could be reduced by increasing aware-
ness of HAE in the scientific community, as well as among
patients. Since it might be difficult to differentiate HAE
symptoms from those of more common angioedemas;
when HAE is suspected, laboratory analysis for C1-INH
levels and function can confirm the deficiency and guide
physicians in making a correct diagnosis and initiating ap-
propriate treatment.
Abbreviations
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